PubMed
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet
Leffler et al., 2015
Healing & RecoveryInvestigationalD
Larazotide
AT-1001
Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- D
- Experience
- 55
- Activity
- 49
Overall check-ins
Trackers & reports
Overview
About Larazotide
Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.
- Category
- Healing & Recovery
- Regulatory status
- Investigational
- Also known as
- AT-1001
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 100% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Digestive upset
6
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 1–2 mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
3
2+ mg
3
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (3)
Source
PubMed
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration
Damianos et al., 2026
PubMed
The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate
Khaleghi et al., 2016
Tools
Explore more
Explore
More ways to learn about Larazotide from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Larazotide?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Larazotide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Larazotide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Larazotide?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Larazotide safe to use?
This wiki does not assess safety or recommend use. Larazotide is listed as Investigational. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Larazotide?
This wiki summarizes observational community reports and linked citations for Larazotide. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Larazotide for study-level context — not medical advice.
What is the legal status of Larazotide?
Larazotide is listed in PeptIQ as Investigational. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Larazotide?
Safety data quality for Larazotide varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Larazotide?
This page links 3 indexed sources for Larazotide. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.